Redmile Group, LLC, Director at IGM Biosciences, Inc. (IGMS), bought 216,078 shares at $9.42 ($2.0M) on 2023-06-29, disclosed to the SEC on 2023-07-03.
Open-market purchase of $2.0M IGMS by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.42 | 54,740 | $516K | 25.4% |
| 2 | $9.42 | 80,423 | $758K | 37.3% |
| 3 | $9.42 | 80,423 | $758K | 37.3% |
| 4 | $0.00 | 492 | $0 | 0.0% |
| Total | $9.40 avg | 216,078 | $2.0M | 100% |
| Filing → |
| FATE | BUY | 2023-12-28 | $332K | — | Filing → |
| ZYME | BUY | 2022-10-18 | $153K | — | Filing → |
| TRDA | BUY | 2021-11-04 | $20.0M | — | Filing → |